Protagonist Therapeutics to Present Rusfertide Phase 2 Study Follow-up at 2024 EHA Congress

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) has announced the presentation of new data from their Phase 2 REVIVE open label extension study of rusfertide at the European Hematology Association (EHA) Congress, scheduled to take place in Madrid from June 13-16, 2024. This data will be highlighted in an oral presentation, along with a published abstract detailing the absence of QTc prolongation in healthy subjects treated with rusfertide.

The EHA Congress presentation will feature an oral session titled "Updated Long-Term Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Polycythemia Vera Patients (Pts): Hematocrit Control and Therapeutic Phlebotomy (Tp) Frequency." This session will be presented by Dr. Kristen M. Pettit from the Department of Internal Medicine, Division of Hematology/Oncology at the University of Michigan, Ann Arbor. The presentation is scheduled for Friday, June 14th, 2024, from 14:45 to 16:00 CEST in Hall Goya 2.

In addition to the oral presentation, the EHA Congress will also feature a published abstract titled "Absence of QTc Prolongation with Rusfertide, a Hepcidin Mimetic for the Treatment of Polycythemia Vera: a Thorough QT/QTc Study in Healthy Subjects," authored by Nishit Modi, SVP of Clinical Pharmacology at Protagonist Therapeutics.

Protagonist Therapeutics is a biopharmaceutical company that focuses on developing peptide-based new chemical entities (NCEs). The company has two advanced clinical-stage drug candidates: rusfertide and JNJ-2113 (formerly known as PN-235). Both of these candidates have been developed from Protagonist's proprietary technology platform. JNJ-2113 was discovered through a collaboration with JNJ scientists as part of Protagonist's Interleukin-23 receptor (IL-23R) program and has progressed through pre-clinical and early clinical stages, with JNJ now overseeing further clinical development.

Rusfertide, a mimetic of the natural hormone hepcidin, is Protagonist's leading drug candidate and is currently undergoing a global Phase 3 development program. The Phase 2 REVIVE study's randomized portion has been completed and unblinded, revealing positive results, and an open-label extension is currently in progress. Additionally, the Phase 3 VERIFY study of rusfertide in polycythemia vera is ongoing. Rusfertide's development and commercialization are being carried out in collaboration with Takeda, following a worldwide collaboration and license agreement established in January 2024. This agreement will take effect upon the conclusion of any applicable waiting periods under the Hart-Scott-Rodino Act.

Protagonist Therapeutics' focus on peptide-based drug candidates and its collaboration with partners such as Takeda and JNJ underscores its commitment to advancing its clinical pipeline. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!